Located at the Global Cardiovascular Innovation Center in Cleveland, Ohio, Cleveland Cord Blood Center scientists are conducting innovative research in the development of stem cell treatments to address unmet medical needs in patients suffering from Parkinson’s disease, diabetes, and those with wound healing issues.
CCBC researchers are spearheading the generation of special immune cells called ‘inducible T regulatory (iTreg) cells for patients with immune disorders like Type 1 diabetes. The hope is that iTregs from cord blood will dampen the effects of diabetes in the pancreas, so the patient is not dependent on daily insulin injections.
Early laboratory studies are investigating stem cell therapy for patients with Parkinson’s disease. Researchers are investigating a cellular therapy based treatment to support and regenerate special cells in the brain that produce dopamine, an important chemical that is decreased in the brain of Parkinson’s disease patients.
Studies are underway to develop novel, off-the-shelf wound healing products that support killing of bacteria, and treating patients with infected non-healing wounds.
CCBC plans are to take the researchers’ initial proof of concept to intellectual property development, and ultimately take these discoveries into patient studies that aim to prove safety and efficacy in the clinical setting. These ‘bench to bedside’ studies are very focused on expanding the use of cord blood as treatment in novel medical applications.